Athersys, Inc.  

(Public, NASDAQ:ATHX)   Watch this stock  
Find more results for Harrington Campbell
1.66
0.00 (0.00%)
Pre-market: 1.71 +0.05 (3.01%)
Jul 24, 8:44AM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.08 - 4.33
Open     -
Vol / Avg. 200.00/463,370.00
Mkt cap 127.90M
P/E     -
Div/yield     -
EPS -0.51
Shares 77.05M
Beta 1.14
Inst. own 36%
Aug 11, 2014
Q2 2014 Athersys Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 11, 2014
Q2 2014 Athersys, Inc. Earnings Release - 4:00PM EDT - Add to calendar
May 8, 2014
Q1 2014 Athersys, Inc. Earnings Conference Call
May 8, 2014
Q1 2014 Athersys, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -1624.33% -1260.99%
Operating margin -1045.12% -1003.16%
EBITD margin - -988.97%
Return on average assets -112.65% -99.51%
Return on average equity -186.18% -153.45%
Employees 56 -
CDP Score - -

Address

3201 Carnegie Avenue
CLEVELAND, OH 44115-2634
United States - Map
+1-216-4319900 (Phone)
+1-216-3619495 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Athersys Inc. is a biopharmaceutical company engaged in the field of regenerative medicine. During the year ended December 31, 2011 the Company is developing its platform product, MultiStem, a allogeneic stem cell product that has been evaluated in two completed Phase I clinical trials and as of December 31, 2011, is being evaluated in two ongoing Phase II clinical trials. The Company�s clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The Company is also engaged in the development of small molecule therapies to treat obesity and other conditions. During 2011, the Company is focused on the development of potent, highly selective compounds that act through stimulation of a specific receptor in the brain that controls appetite, the 5HT2c serotonin receptor.

Officers and directors

Gil Van Bokkelen Ph.D. Chairman of the Board, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
William Jr Lehmann Jr., J.D. President, Chief Operating Officer
Age: 47
Bio & Compensation  - Reuters
John J. Harrington Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 46
Bio & Compensation  - Reuters
Robert J. Deans Ph.D. Executive Vice President - Regenerative Medicine
Age: 61
Bio & Compensation  - Reuters
Laura K. Campbell CPA Vice President - Finance
Age: 49
Bio & Compensation  - Reuters
Lee E. Babiss Lead Independent Director
Age: 58
Bio & Compensation  - Reuters
Ismail Kola Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Lorin Jeffry Randall Independent Director
Age: 70
Bio & Compensation  - Reuters
Kenneth H. Traub Independent Director
Age: 52
Bio & Compensation  - Reuters
Jack L. Wyszomierski Independent Director
Age: 58
Bio & Compensation  - Reuters